Zai Lab (09688) saw its shares rise more than 5% in early trading. At the time of writing, the stock was up 2.38% to HK$15.49, with a turnover of HK$73.7089 million. On the news front, on May 11, according to an announcement from Zai Lab's official WeChat account, the company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to zocilurtatug pelitecan (zoci, formerly known as ZL-1310), an antibody-drug conjugate (ADC) targeting Delta-like ligand 3 (DLL3) with potential as a first-in-class therapy. This designation is for the treatment of extensive-stage poorly differentiated neuroendocrine carcinomas (epNECs) that have progressed after first-line standard therapy. Previously, at the American Association for Cancer Research (AACR) 2026 Annual Meeting, Zai Lab presented encouraging preliminary data from an ongoing, registration-supportive Phase 1b/2 multicenter clinical study of zoci for epNEC and other specific solid tumors.